CCM
RETA

CAAS Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

CAAS Capital Management’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,400
Closed -$530K – 640
2020
Q2 		$530K Buy
3,400
+1,400
+70% +$213K 0.02% 310
2020
Q1 		$289K Buy
+2,000
New +$386K 0.03% 194

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

CAAS Capital Management's RETA Position: Q1 2021 in Review

CAAS Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2021, closing a stake of 95,288 shares — an estimated $11.8M sold.

CAAS Capital Management first reported a position in RETA in Q4 2020 and held it in 1 quarter. The position peaked at $11.8M in Q4 2020. 201 funds tracked by Wall St. Rank hold RETA as of Q1 2021.

  • CAAS Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2021 after selling out during the quarter.
  • CAAS Capital Management sold 95,288 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2021, an estimated $11.8M.
  • CAAS Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2020 and held it in 1 quarter.
  • CAAS Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $11.8M in Q4 2020.
  • 201 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2021.

Based on CAAS Capital Management's 13F filing for Q1 2021, filed 17 May 2021.